Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.